Revance Therapeutics, Inc.
RVNC
RVNC was delisted on the 5th of February, 2025.
188 hedge funds and large institutions have $411M invested in Revance Therapeutics, Inc. in 2024 Q1 according to their latest regulatory filings, with 38 funds opening new positions, 60 increasing their positions, 54 reducing their positions, and 41 closing their positions.
70% more call options, than puts
Call options by funds: $4.96M | Put options by funds: $2.92M
11% more repeat investments, than reductions
Existing positions increased: 60 | Existing positions reduced: 54
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
7% less first-time investments, than exits
New positions opened: 38 | Existing positions closed: 41
3% less funds holding
Funds holding: 193 → 188 (-5)
36% less capital invested
Capital invested by funds: $644M → $411M (-$233M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Barclays
London,
United Kingdom
|
+$15.8M |
| 2 |
Capital World Investors
Los Angeles,
California
|
+$11.9M |
| 3 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$11.7M |
| 4 |
SCM
Suvretta Capital Management
New York
|
+$9.47M |
| 5 |
Franklin Resources
San Mateo,
California
|
+$9.08M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
-$9.18M |
| 2 |
Jennison Associates
New York
|
-$9.07M |
| 3 |
JP Morgan Chase
New York
|
-$8.82M |
| 4 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$4.43M |
| 5 |
IHAM
Integral Health Asset Management
New York
|
-$3.96M |
RVNC Hedge Fund Activity: Q1 2024 in Review
188 of the 6,943 institutional investors tracked by Wall St. Rank reported a position in Revance Therapeutics, Inc. (RVNC) for Q1 2024, worth a combined $411M — down 36% from $644M a quarter earlier.
Sellers outnumbered buyers: 41 funds closed out of RVNC and 38 opened new positions — a net loss of 3 holders — while 54 trimmed existing stakes and 60 added.
The largest buyer was Barclays, adding an estimated $15.8M. The largest seller was Invesco, cutting an estimated $9.18M.
- 188 institutional investors held Revance Therapeutics, Inc. (RVNC) as of Q1 2024, down from 193 in Q4 2023.
- Funds reported $411M of Revance Therapeutics, Inc. stock for Q1 2024, down 36% quarter-over-quarter.
- 38 funds opened new Revance Therapeutics, Inc. positions in Q1 2024 and 41 closed out, a net change of -3 holders.
- The largest Revance Therapeutics, Inc. buyer in Q1 2024 was Barclays, an estimated $15.8M added.
- The largest Revance Therapeutics, Inc. seller in Q1 2024 was Invesco, an estimated $9.18M sold.
Based on aggregated 13F filings for Q1 2024.